Amgen Inc. (NASDAQ:AMGN) Maintains "Hold" Rating by UBS Amid Industry Engagement

Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies. It focuses on developing and manufacturing human therapeutics, with a strong portfolio of drugs targeting serious illnesses. Amgen competes with other biotech giants like Gilead Sciences and Biogen. On May 2, 2025, UBS updated its rating for Amgen to Neutral, maintaining a hold action, with the stock priced at approximately $278.63.

Amgen's first-quarter 2025 results were impressive, surpassing both earnings and sales estimates. The company's adjusted earnings per share reached $4.90, exceeding the Zacks Consensus Estimate of $4.16, marking a 24% increase from the previous year. This growth was driven by higher revenues, although partially offset by increased operating costs.

Total revenues for the quarter amounted to $8.1 billion, surpassing the expected $7.95 billion and reflecting a 9% year-over-year increase. Product revenues specifically rose by 11% to $7.87 billion, with a 14% increase in volumes, despite ongoing price declines. This indicates strong demand for Amgen's products.

Key drugs such as Prolia, Xgeva, Repatha, Blincyto, and Evenity all exceeded sales expectations. Prolia, in particular, generated $1.1 billion in revenue, a 10% increase from the previous year, outperforming the Zacks Consensus Estimate of $994 million. This strong performance was attributed to higher volumes, which offset the impact of lower pricing.

Currently, Amgen's stock price is $278.70, reflecting a decrease of 1.79% or $5.08. Today, the stock has traded as low as $275.20 and as high as $291.61. Over the past year, the stock has reached a high of $346.85 and a low of $253.30. Amgen's market capitalization stands at approximately $149.84 billion, with a trading volume of 2,104,535 shares on the NASDAQ exchange.

Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies. It focuses on developing and manufacturing human therapeutics, with a strong portfolio of drugs targeting serious illnesses. Amgen competes with other biotech giants like Gilead Sciences and Biogen. On May 2, 2025, UBS updated its rating for Amgen to Neutral, maintaining a hold action, with the stock priced at approximately $278.63.

Amgen's first-quarter 2025 results were impressive, surpassing both earnings and sales estimates. The company's adjusted earnings per share reached $4.90, exceeding the Zacks Consensus Estimate of $4.16, marking a 24% increase from the previous year. This growth was driven by higher revenues, although partially offset by increased operating costs.

Total revenues for the quarter amounted to $8.1 billion, surpassing the expected $7.95 billion and reflecting a 9% year-over-year increase. Product revenues specifically rose by 11% to $7.87 billion, with a 14% increase in volumes, despite ongoing price declines. This indicates strong demand for Amgen's products.

Key drugs such as Prolia, Xgeva, Repatha, Blincyto, and Evenity all exceeded sales expectations. Prolia, in particular, generated $1.1 billion in revenue, a 10% increase from the previous year, outperforming the Zacks Consensus Estimate of $994 million. This strong performance was attributed to higher volumes, which offset the impact of lower pricing.

Currently, Amgen's stock price is $278.70, reflecting a decrease of 1.79% or $5.08. Today, the stock has traded as low as $275.20 and as high as $291.61. Over the past year, the stock has reached a high of $346.85 and a low of $253.30. Amgen's market capitalization stands at approximately $149.84 billion, with a trading volume of 2,104,535 shares on the NASDAQ exchange.

• UBS maintains a "Hold" rating for Amgen Inc. (NASDAQ:AMGN) with a stock price of $295.06.
• Amgen showcased its strategies and developments at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
• The company's stock price reflects a slight decrease, indicating some volatility in its market performance.

Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies and treatments. On February 12, 2025, UBS maintained its "Hold" rating for Amgen, with the stock priced at $295.06. This decision comes amidst Amgen's active participation in industry events, such as the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

At the conference, Amgen was represented by key figures like Narimon Honarpour, Senior Vice President of Global Development, and Justin Claeys, Head of Investor Relations. The event, moderated by Oppenheimer's biotech analyst Jay Olson, allowed Amgen to discuss its strategies and developments in the healthcare sector. This engagement highlights Amgen's commitment to maintaining transparency and communication with investors.

Amgen's stock price of $295.06 reflects a slight decrease of 0.54%, or $1.60, from previous levels. Throughout the trading day, the stock fluctuated between $292.63 and $296.20. Over the past year, Amgen's stock has seen a high of $346.85 and a low of $253.30, indicating some volatility in its market performance.

With a market capitalization of approximately $158.6 billion, Amgen remains a significant player in the biotechnology industry. The company's stock is actively traded, with a current volume of 2,389,926 shares. This level of trading activity suggests continued investor interest and engagement with Amgen's market performance.

Amgen Inc. (NASDAQ:AMGN) delivered stronger-than-expected fourth-quarter earnings, but a cautious profit forecast for 2025 dampened investor sentiment, sending shares down over 1% in pre-market today.

In Q4, the biotech giant saw its revenue climb 11% year over year to $9.1 billion, surpassing analysts’ projections of $8.85 billion. Adjusted earnings per share reached $5.31, comfortably exceeding the expected $5.04. The company benefited from strong product sales, which surged 19% in 2024, primarily fueled by a 23% increase in volume. However, pricing pressures slightly offset these gains.

Despite the impressive quarterly performance, Wall Street’s focus shifted to Amgen’s guidance for 2025, which fell short of expectations. The company expects earnings per share to land between $20.00 and $21.20, with the midpoint of $20.60 falling below the $20.82 analysts had anticipated. Full-year revenue is projected at $34.3 billion, just shy of the $34.53 billion consensus forecast.

While Amgen’s total revenue for 2024 grew by 19% to $33.4 billion, investors appeared more concerned with the company’s ability to sustain momentum into the new year. With market pressures and pricing challenges looming, the coming quarters will be key in determining whether Amgen can keep up its growth trajectory.

Amgen Inc. (NASDAQ:AMGN) delivered stronger-than-expected fourth-quarter earnings, but a cautious profit forecast for 2025 dampened investor sentiment, sending shares down over 1% in pre-market today.

In Q4, the biotech giant saw its revenue climb 11% year over year to $9.1 billion, surpassing analysts’ projections of $8.85 billion. Adjusted earnings per share reached $5.31, comfortably exceeding the expected $5.04. The company benefited from strong product sales, which surged 19% in 2024, primarily fueled by a 23% increase in volume. However, pricing pressures slightly offset these gains.

Despite the impressive quarterly performance, Wall Street’s focus shifted to Amgen’s guidance for 2025, which fell short of expectations. The company expects earnings per share to land between $20.00 and $21.20, with the midpoint of $20.60 falling below the $20.82 analysts had anticipated. Full-year revenue is projected at $34.3 billion, just shy of the $34.53 billion consensus forecast.

While Amgen’s total revenue for 2024 grew by 19% to $33.4 billion, investors appeared more concerned with the company’s ability to sustain momentum into the new year. With market pressures and pricing challenges looming, the coming quarters will be key in determining whether Amgen can keep up its growth trajectory.

• Amgen Inc. (NASDAQ:AMGN) is set to release its quarterly earnings with an expected EPS of $5.11 and revenue of $8.52 billion.
• The company declared a dividend of $2.25 per share for Q4 2024, highlighting its commitment to shareholder value.
• Amgen's financial metrics reveal a high debt-to-equity ratio of 10.57 and a P/E ratio of 54.42, indicating significant financial leverage and high market valuation.

Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company based in Thousand Oaks, California. It focuses on developing innovative therapies for serious illnesses. Amgen is known for its strong portfolio of drugs, but it faces challenges due to the expiration of key patents. The company competes with other biotech giants like Biogen and Gilead Sciences.

Amgen is set to release its quarterly earnings on October 30, 2024. Analysts expect an earnings per share (EPS) of $5.11 and revenue of approximately $8.52 billion. Despite these projections, the earnings report may not significantly impact the stock price due to increased research and development spending and the expiration of key drug patents.

Amgen's Board of Directors has declared a dividend of $2.25 per share for the fourth quarter of 2024, as highlighted by PR Newswire. This move underscores Amgen's commitment to returning value to shareholders. The company's financial metrics, such as a high debt-to-equity ratio of 10.57, indicate significant financial leverage, which investors should consider.

Amgen's new pipeline drugs, particularly the weight-loss drug Mari-Tide, offer potential for future growth. Positive Phase 2 data for Mari-Tide could boost Amgen's market capitalization. Investors are keenly awaiting updates on this drug, which could transform Amgen's growth trajectory.

Amgen's financial metrics provide insight into its market valuation. With a P/E ratio of 54.42 and a price-to-sales ratio of 5.53, the market values Amgen's earnings and revenue highly. The company's enterprise value to sales ratio of 7.26 and enterprise value to operating cash flow ratio of 34.71 further reflect its valuation relative to sales and cash flow.